Insider Transactions in Q2 2021 at Novo Cure LTD (NVCR)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
23,540
-23.24%
|
$5,061,100
$215.0 P/Share
|
|
Jun 09
2021
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
814
+1.1%
|
-
|
|
Jun 09
2021
|
David Hung |
BUY
Grant, award, or other acquisition
|
Direct |
814
+10.81%
|
-
|
|
Jun 09
2021
|
Jeryl L Hilleman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,270
-30.14%
|
$266,700
$210.01 P/Share
|
|
Jun 09
2021
|
Jeryl L Hilleman |
BUY
Grant, award, or other acquisition
|
Direct |
814
+16.19%
|
-
|
|
Jun 09
2021
|
W Anthony Vernon |
BUY
Grant, award, or other acquisition
|
Direct |
814
+0.5%
|
-
|
|
Jun 09
2021
|
Martin J. Madden |
BUY
Grant, award, or other acquisition
|
Direct |
814
+4.95%
|
-
|
|
Jun 09
2021
|
Sherilyn S Mc Coy Director |
BUY
Grant, award, or other acquisition
|
Direct |
814
+10.81%
|
-
|
|
Jun 07
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
1,000
-1.37%
|
$204,000
$204.55 P/Share
|
|
Jun 07
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.35%
|
$31,000
$31.45 P/Share
|
|
May 27
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,833
-5.93%
|
$366,600
$200.0 P/Share
|
|
May 27
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+5.6%
|
$86,151
$47.56 P/Share
|
|
May 12
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,943
-6.27%
|
$349,740
$180.48 P/Share
|
|
May 11
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,262
-6.8%
|
$407,160
$180.12 P/Share
|
|
May 10
2021
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
5,650
-7.85%
|
$1,067,850
$189.65 P/Share
|
|
May 10
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,846
+9.34%
|
$180,762
$47.56 P/Share
|
|
May 10
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,833
-5.22%
|
$346,437
$189.65 P/Share
|
|
May 10
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+4.96%
|
$86,151
$47.56 P/Share
|
|
May 05
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
1,000
-1.37%
|
$199,000
$199.67 P/Share
|
|
May 05
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.35%
|
$31,000
$31.45 P/Share
|
|
May 05
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
1,290
-1.26%
|
$256,710
$199.67 P/Share
|
|
May 04
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
1,043
-1.01%
|
$208,600
$200.86 P/Share
|
|
May 03
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,333
+2.2%
|
$475,932
$204.1 P/Share
|
|
Apr 13
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,958
-5.53%
|
$1,191,600
$200.0 P/Share
|
|
Apr 13
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,958
+5.16%
|
$393,228
$66.74 P/Share
|
|
Apr 13
2021
|
Gabriel Leung |
SELL
Open market or private sale
|
Direct |
6,000
-3.92%
|
$1,194,000
$199.0 P/Share
|
|
Apr 13
2021
|
Gabriel Leung |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+7.14%
|
$186,000
$31.45 P/Share
|
|
Apr 13
2021
|
Asaf Danziger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
97,973
-92.29%
|
$19,202,708
$196.34 P/Share
|
|
Apr 13
2021
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
95,000
-0.71%
|
$19,285,000
$203.1 P/Share
|
|
Apr 01
2021
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
7,928
-1.2%
|
$1,062,352
$134.12 P/Share
|